Every decision needs a compass.  
For cancer treatment, it’s Polaris™

‍

Polaris™

Our platform seamlessly links histology, RNASeq, and patient outcomes at scale, creating an integrated view of spatial biology that drives deeper insights and novel cancer biology discoveries¹.

1. El Nahhas, O.S.M., van Treeck, M., Wölflein, G. et al. From whole-slide image to biomarker prediction: end-to-end weakly supervised deep learning in computational pathology. Nat Protoc 20, 293–316 (2025). https://www.nature.com/articles/s41596-024-01047-2

Polaris™ Breast

Our first diagnostic assesses metastatic risk in early breast cancer directly from digitized histology slides, helping refine adjuvant treatment options. The scientific foundation of Polaris™ Breast has been validated on more than 6,000 patients² and is available for research use only while undergoing regulatory approval in the EU and US.

2. Boehm, K.M., El Nahhas, O.S.M., Marra, A. et al. Multimodal histopathologic models stratify hormone receptor-positive early breast cancer. Nat Commun 16, 2106 (2025). https://www.nature.com/articles/s41467-025-57283-x

News

StratifAI Raises €12.5M for Clinical Validation of AI Biomarker Platform Polaris™ for Precision Oncology

30/9/2025

29/9/2025

Oversubscribed round led by Picus Capital and Alven will fast-track clinical validation of AI-based Cancer-Biomarker Platform Polaris™, expand global reach, and unlock multi‑billion‑euro cancer diagnostics market.

StratifAI raises €1.5M in pre-seed funding to advance AI-based precision oncology

2/9/2024

22/9/2025

Investment round from leading VCs and strategic partners to accelerate development of innovative digital oncology platform

We are hiring!
Check out our open positions

Careers

Every decision needs a compass. For cancer treatment, it’s Polaris™